HARE-40: HPV Anti-CD40 RNA vaccinE

NCT03418480 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Human Papilloma Virus Related Carcinoma
Head and Neck Neoplasm
Cervical Neoplasm
Penile Neoplasms Malignant
Unknown Primary Tumors

Interventions

DRUG: BNT113

Sponsor

University of Southampton

Collaborators

[object Object]